Dr. Romesh Subramanian Ph.D. is the Co-Founder & Advisor at Dyne Therapeutics.
As the Co-Founder & Advisor of Dyne Therapeutics, the total compensation of Dr D at Dyne Therapeutics is $565,170. There are 3 executives at Dyne Therapeutics getting paid more, with Dewei Qiao having the highest compensation of $2,036,560.
Dr D is 55, he's been the Co-Founder & Advisor of Dyne Therapeutics since . There are 4 older and 20 younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics, Inc. is Yuezhou Ou, 68, who is the Independent Non-Executive Director.
Romesh's mailing address filed with the SEC is C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes y Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: